Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Illicit stimulant use is associated with abnormal substantia nigra morphology in humans.

Todd G, Noyes C, Flavel SC, Della Vedova CB, Spyropoulos P, Chatterton B, Berg D, White JM.

PLoS One. 2013;8(2):e56438. doi: 10.1371/journal.pone.0056438. Epub 2013 Feb 13.

2.

Adults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonism.

Todd G, Pearson-Dennett V, Wilcox RA, Chau MT, Thoirs K, Thewlis D, Vogel AP, White JM.

Parkinsonism Relat Disord. 2016 Apr;25:27-32. doi: 10.1016/j.parkreldis.2016.02.019. Epub 2016 Feb 21.

PMID:
26923520
3.

Illicit stimulant use in humans is associated with a long-term increase in tremor.

Flavel SC, Koch JD, White JM, Todd G.

PLoS One. 2012;7(12):e52025. doi: 10.1371/journal.pone.0052025. Epub 2012 Dec 18.

4.

Motor cortex and corticospinal excitability in humans with a history of illicit stimulant use.

Flavel SC, White JM, Todd G.

J Appl Physiol (1985). 2012 Nov;113(9):1486-94. doi: 10.1152/japplphysiol.00718.2012. Epub 2012 Sep 6.

5.

Sonography for diagnosis of Parkinson disease-from theory to practice: a study on 300 participants.

Alonso-Cánovas A, López-Sendón JL, Buisán J, deFelipe-Mimbrera A, Guillán M, García-Barragán N, Corral I, Matute-Lozano MC, Masjuan J, Martínez-Castrillo JC, Walter U.

J Ultrasound Med. 2014 Dec;33(12):2069-74. doi: 10.7863/ultra.33.12.2069.

PMID:
25425362
6.

Light pigmentation phenotype is correlated with increased substantia nigra echogenicity.

Rumpf JJ, Schirmer M, Fricke C, Weise D, Wagner JA, Simon J, Classen J.

Mov Disord. 2015 Nov;30(13):1848-52. doi: 10.1002/mds.26427. Epub 2015 Sep 23.

PMID:
26395561
7.

Hand function is altered in individuals with a history of illicit stimulant use.

Pearson-Dennett V, Flavel SC, Wilcox RA, Thewlis D, Vogel AP, White JM, Todd G.

PLoS One. 2014 Dec 29;9(12):e115771. doi: 10.1371/journal.pone.0115771. eCollection 2014.

8.

Structural abnormality of substantia nigra induced by methamphetamine abuse.

Rumpf JJ, Albers J, Fricke C, Mueller W, Classen J.

Mov Disord. 2017 Dec;32(12):1784-1788. doi: 10.1002/mds.27205. Epub 2017 Oct 30.

PMID:
29082542
9.

Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder.

Iranzo A, Stockner H, Serradell M, Seppi K, Valldeoriola F, Frauscher B, Molinuevo JL, Vilaseca I, Mitterling T, Gaig C, Vilas D, Santamaria J, Högl B, Tolosa E, Poewe W.

Mov Disord. 2014 Dec;29(14):1774-80. doi: 10.1002/mds.26055. Epub 2014 Nov 10.

PMID:
25384461
10.

Hyperechogenicity of the substantia nigra in Parkinson's disease.

Ressner P, Skoloudík D, Hlustík P, Kanovský P.

J Neuroimaging. 2007 Apr;17(2):164-7.

PMID:
17441838
11.

Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor.

Sprenger FS, Wurster I, Seppi K, Stockner H, Scherfler C, Sojer M, Schmidauer C, Berg D, Poewe W.

Mov Disord. 2016 Apr;31(4):579-83. doi: 10.1002/mds.26515. Epub 2016 Feb 19.

PMID:
26893155
12.

Life-long increase of substantia nigra hyperechogenicity in transcranial sonography.

Hagenah J, König IR, Sperner J, Wessel L, Seidel G, Condefer K, Saunders-Pullman R, Klein C, Brüggemann N.

Neuroimage. 2010 May 15;51(1):28-32. doi: 10.1016/j.neuroimage.2010.01.112. Epub 2010 Feb 10.

PMID:
20152909
13.

[Usefulness of transcranial sonography in Parkinson's disease. A comparative study using 123I-FP-CIT SPECT].

Hernández Vara J, Rubiera del Fueyo M, Lorenzo Bosquet C, Castell Conesa J, Molina Cateriano CA, Rodríguez FM.

Med Clin (Barc). 2008 Sep 13;131(8):285-9. Spanish.

PMID:
18803921
14.

Detection of MPTP-induced substantia nigra hyperechogenicity in Rhesus monkeys by transcranial ultrasound.

Subramanian T, Lieu CA, Guttalu K, Berg D.

Ultrasound Med Biol. 2010 Apr;36(4):604-9. doi: 10.1016/j.ultrasmedbio.2009.12.001. Epub 2010 Mar 7.

15.

Severity of restless legs syndrome is inversely correlated with echogenicity of the substantia nigra in different neurodegenerative movement disorders. a preliminary observation.

Pedroso JL, Bor-Seng-Shu E, Felicio AC, Braga-Neto P, Dutra LA, de Aquino CC, Ferraz HB, do Prado GF, Teixeira MJ, Barsottini OG.

J Neurol Sci. 2012 Aug 15;319(1-2):59-62. doi: 10.1016/j.jns.2012.05.015. Epub 2012 May 24.

PMID:
22632781
16.

No correlation of substantia nigra echogenicity and nigrostriatal degradation in Parkinson's disease.

Lobsien E, Schreiner S, Plotkin M, Kupsch A, Schreiber SJ, Doepp F.

Mov Disord. 2012 Mar;27(3):450-3. doi: 10.1002/mds.24070. Epub 2012 Jan 11.

PMID:
22237792
17.

Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography.

Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K.

Neurology. 1995 Jan;45(1):182-4.

PMID:
7824114
18.

[Evaluation of the substantia nigra by means of transcranial ultrasound imaging].

Vivo-Orti MN, Tembl JI, Sastre-Bataller I, Vazquez-Costa JF, Sahuquillo P, Burguera JA.

Rev Neurol. 2013 Mar 1;56(5):268-74. Spanish.

19.

Substantia Nigra Hyperechogenicity: Validation of Transcranial Sonography for Parkinson Disease Diagnosis in a Large Estonian Cohort.

Toomsoo T, Liepelt-Scarfone I, Kerner R, Kadastik-Eerme L, Asser T, Rubanovits I, Berg D, Taba P.

J Ultrasound Med. 2016 Jan;35(1):17-23. doi: 10.7863/ultra.14.12069. Epub 2015 Nov 20.

PMID:
26589647
20.

Substantia nigra echogenicity correlated with clinical features of Parkinson's disease.

Zhou HY, Sun Q, Tan YY, Hu YY, Zhan WW, Li DH, Wang Y, Xiao Q, Liu J, Chen SD.

Parkinsonism Relat Disord. 2016 Mar;24:28-33. doi: 10.1016/j.parkreldis.2016.01.021. Epub 2016 Jan 26.

PMID:
26842545

Supplemental Content

Support Center